The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Edison well respected and have a accurate track record have under valued at 44.4 a share, simply because so few shares are available, Won,t sell as takeover possibilities/ or further developments reduce the risk to the upside.
As most already know Woodford sold tissue and Abzena to fund a average down on the Northwest Bio, and a legal challenge. Only he knows why he cut is stake to 14%, hence the share price fall and the spread. Anyway away Woodford Tissue is growing in strength just be patient this will deliver.
Woodford built up the stake Invesco Perpetual hold when he was managing that fund, and they still hold a substantial holding. He came in at the start. On starting CF Woodford Tissue was one of the first shares he purchased in his new fund.This is a good story albeit its taking a little longer than first expected. In 2014 the Chairman stated he expected Tissue to become a takeover target as the products roll out. I have been here since 2012 holding at 10.5pence have seen 30p but expect we will surpass that in the not to distant future.
Its unlikely the Hardman report will have much influence, the 800k a month burn is what the company has forecast. What we need is sales to cut that burn figure this year, any drop in burn should be market positive. The first million in sales as per RNS is surely ahead of schedule. So in my view steady as she goes and with patience our rewards could be in line with the my expectations
Revenue coming through to what would be until the end of June as there is about a thirty day turn around with most medi care companies. the next six months revenue will tell much more than today. Its only just got going and surely some suitors are watching this space..
That is why its off most peoples radar, but not Neil Woodford's or mine. Unique technology also being tested in the manufacturing industry. Hard to see this technology not being used worldwide.
With only one third of the shares in public hands, and no major share holders unloading its difficult to put the recent volatility into any perspective, I have spent many hours today researching Tissue and cannot come up with anything. Any one else got any info?.
The spread suggests there is not a major increase in activity around the share price, but again increasing the sales force would suggest the current reps are working at full capacity, and just maybe this is the start of a move forward during the coming months.
I agree I will try your suggestion, thanks for the great informative posts on the Centamin board.
This market cannot be manipulated like the aim, investors are to smart, But market makers will try to move the price down using shorts, UT trades, 7.50AM Auctions. Hold tight I am through research sure these will be big numbers on new business and funds under management. Many new partners, with little serious competition from the fee based based sector. Top quality wealth management from very qualified advisers. Lets look forward to this posh company delivering to investors golden flip flops
The recent retail distribution review (RDR) will have been extremely helpful to St James's place with recruiting top quality advisers, I think this will have resulted in a steep increase in adviser numbers that will translate into very powerful new business figures on the 22nd. I suspect numbers will beat expectations.
It appears the uptrend has been eroded by some selling pressure, this is a regular occurrence when we try to break out. With no news since the launch and no figures due until the 8th October we are a little in the dark with regards to sales. (I am unable to find any news). It is tempting to take some profit but as an acquisition target I am reluctant to do so as the lower the price the more attractive to suitors we become. With Invesco having 29% of the voting rights and Ballie Gifford over 5% this hopefully is reassuring going forward alongside the increase in sales staff from 25 to 80 lets hope we get some news soon.
I am a retired finance director of my own company started from scratch in 1979. I have been following Tissue from the start this company has good management great research teams ( surprised they have held onto such top quality for so long) the potential that is being showed by the development team is above the level it should be the speedy patient applications. The future markets for the products is quiet frankly astounding. I am sure vultures won't let this stock get onto the radar before we have have a takeover bid. 8 years on the board only my second post.